Office for Disease Control and Emergency Response, Chinese Centre for Disease Control and Prevention, Beijing, China.
BMJ. 2010 Sep 28;341:c4779. doi: 10.1136/bmj.c4779.
To describe the clinical features and effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A(H1N1) virus infection.
Opportunistic retrospective review of medical charts of patients with confirmed 2009 H1N1 identified through the national surveillance system in China from May to July 2009.
Under coordination of the Ministry of Health, local health departments were asked to collect medical records of confirmed patients and send them to the Chinese Centre for Disease Control and Prevention on a voluntary basis as part of the public health response. Population 1291 patients with confirmed 2009 H1N1 infection and available data for chart review.
Demographic characteristics, comorbidities, symptoms and signs, laboratory tests, findings on chest radiography, antiviral treatment, duration of fever, and duration of viral RNA shedding.
The median age of 1291 patients was 20 years (interquartile range 12-26); 701 (54%) were male. The most common symptoms were fever (820, 64%), cough (864, 67%), sore throat (425, 33%), sputum (239, 19%), and rhinorrhoea (228, 18%). Of 920 patients who underwent chest radiography, 110 (12%) had abnormal findings consistent with pneumonia. Some 983 (76%) patients were treated with oseltamivir from a median of the third day of symptoms (2-4). No patients required admission to the intensive care unit or mechanical ventilation. 2009 H1N1 was shed from one day before onset of symptoms to up to eight days after onset in most (91%) patients, with a median of 5 (3-6) days of shedding after onset. Treatment with oseltamivir significantly protected against subsequent development of radiographically confirmed pneumonia (odds ratio 0.12, 95% confidence interval 0.08 to 0.18), and treatment started within two days of symptom onset reduced the duration of fever and viral RNA shedding.
Chinese patients with 2009 H1N1 infection predominantly presented with features of uncomplicated, self limiting acute respiratory illness. 2009 H1N1 might be shed longer than seasonal influenza virus. Treatment with oseltamivir was associated with a significantly reduced development of radiographically confirmed pneumonia and a shorter duration of fever and viral RNA shedding. Though these patients benefited from treatment, the findings should be interpreted with caution as the study was retrospective and not all patients underwent chest radiography.
描述奥司他韦对轻症大流行 2009 年甲型 H1N1 流感病毒感染患者疾病进展和病毒 RNA 脱落的临床效果。
对 2009 年 5 月至 7 月通过中国国家监测系统发现的确诊 2009 年 H1N1 患者的病历进行回顾性观察性研究。
在中国,在卫生部的协调下,地方卫生部门被要求收集确诊患者的病历,并作为公共卫生应对措施的一部分,自愿将其发送至中国疾病预防控制中心。人群:1291 例确诊 2009 年 H1N1 感染且病历资料完整可供分析的患者。
人口学特征、合并症、症状和体征、实验室检查、胸部 X 线检查结果、抗病毒治疗、发热持续时间和病毒 RNA 脱落持续时间。
1291 例患者的中位年龄为 20 岁(四分位距 12-26 岁);701 例(54%)为男性。最常见的症状为发热(820 例,64%)、咳嗽(864 例,67%)、咽痛(425 例,33%)、咳痰(239 例,19%)和流涕(228 例,18%)。920 例行胸部 X 线检查的患者中,110 例(12%)的影像学结果与肺炎相符。983 例(76%)患者接受了奥司他韦治疗,中位治疗开始时间为症状出现后的第 3 天(2-4 天)。没有患者需要入住重症监护病房或接受机械通气。大多数(91%)患者的 2009 年 H1N1 病毒从症状出现前 1 天到出现后 8 天均可检出,中位病毒脱落持续时间为症状出现后 5 天(3-6 天)。奥司他韦治疗显著降低了影像学确诊肺炎的发生风险(比值比 0.12,95%置信区间 0.08 至 0.18),症状出现后 2 天内开始治疗可缩短发热和病毒 RNA 脱落时间。
中国的 2009 年 H1N1 感染患者主要表现为无并发症、自限性急性呼吸道疾病特征。2009 年 H1N1 病毒的脱落时间可能长于季节性流感病毒。奥司他韦治疗与影像学确诊肺炎的发生率显著降低和发热及病毒 RNA 脱落时间缩短相关。虽然这些患者从治疗中获益,但鉴于本研究为回顾性研究且并非所有患者均接受了胸部 X 线检查,故研究结果应谨慎解读。